3 - Procaps Group, S.A. (0001863362) (Issuer)

3 - Procaps Group, S.A. (0001863362) (Issuer)

3 - Procaps Group, S.A. (0001863362) (Issuer)

3 - Procaps Group, S.A. (0001863362) (Issuer)

6-K - Procaps Group, S.A. (0001863362) (Filer)

6-K - Procaps Group, S.A. (0001863362) (Filer)

6-K - Procaps Group, S.A. (0001863362) (Filer)

6-K - Procaps Group, S.A. (0001863362) (Filer)

6-K - Procaps Group, S.A. (0001863362) (Filer)

6-K - Procaps Group, S.A. (0001863362) (Filer)

6-K - Procaps Group, S.A. (0001863362) (Filer)

6-K - Procaps Group, S.A. (0001863362) (Filer)

6-K - Procaps Group, S.A. (0001863362) (Filer)

6-K - Procaps Group, S.A. (0001863362) (Filer)

MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that the Company received a notice from The Nasdaq Stock Market LLC ("Nasdaq") that it has determined to delist the Company's ordinary shares on Nasdaq. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules 5250(c)(1) and 5250(c)(2) for failing to file periodic and interim financial reports. As a result of the forgoing, the Company's ordinary shares are expected to commence trading on the Expert Market operated by the OTC

MIAMI and BARRANQUILLA, Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that, as anticipated, on December 31, 2024, the Company received notice from The Nasdaq Stock Market LLC ("Nasdaq") of an additional filing delinquency relating to the Company's interim financial statements for the period ended June 30, 2024. The interim financial statements were required to be filed with Nasdaq by December 31, 2024, but were not for the reasons previously disclosed in connection with the delay in the filing of the Company's Form 20-F for the fiscal yea

MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly app

MIAMI and BARRANQUILLA, Colombia , Dec. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced the successful execution of key strategic transactions and governance updates aimed at strengthening its financial position and supporting long-term growth objectives. On November 29, 2024, the Company entered into a Secured Convertible Note Subscription Agreement with Hoche Partners Pharma Holdings S.A. ("Hoche"), pursuant to which the Company may issue up to $40 million in Convertible Notes. Under the agreement, Procaps issued an initial $20 million Convertible Not

MIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), announced today that, on November 13, 2024, the Company received formal notice from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company's failure to timely file the Form 20-F for the fiscal year ended December 31, 2023 (the "Form 20-F") with the U.S. Securities and Exchange Commission (the "SEC"), the Company no longer satisfied Nasdaq Listing Rule 5250(c)(1) (the "Filing Rule") and its securities are therefore subject to suspension and delisting unless the Company timely requests a hearing

MIAMI and BARRANQUILLA, Colombia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, providing critical updates on the Company's ongoing independent investigation, financial restatement, governance enhancements, and commitment to long-term stability. "Dear Shareholders, As we navigate recent challenges at Procaps, I want to personally reaffirm our dedication to transparency, compliance, and sustainable management. We are committed to addressing the findings from our ongoing investigati

MIAMI and BARRANQUILLA, Colombia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, with updates on the Company's restructuring and strategic plan projects. "Dear Shareholders, We are pleased to update you on several significant developments as we continue to move forward with our strategic plan and financial restructuring efforts. Forbearance Agreements We have successfully signed consolidated forbearance agreements covering approximately an aggregate of $209 million in debt. These ag

MIAMI and BARRANQUILLA, Colombia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, addressing the current state of the business and outlining key strategic priorities for the Company. "Dear Shareholders, When I began my tenure as CEO of Procaps in January 2024, I made a commitment to formulate a strategic plan that steers Procaps towards consistent growth, optimal cash management, and predictable profitability. I said then that to move forward successfully, we must look back, learn

Ruben Minski decides to step down as Executive Chairman and José Minski is appointed as new Chairman of the Board Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that Mr. Ruben Minski has resigned from his role as Executive Chairman of the Board, effective June 30th. Mr. Minski will continue to serve as a member of the Board of Directors. Reflecting on his decision, Ruben stated: "This month marked six months since Jose Antonio Vieira assumed the role of CEO of Procaps. To ensure a smooth and effective transition, I have had the privilege of serving as Executive Chairman of our Board. Reflec

Procaps Group (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it has received a letter from the Nasdaq Stock Market, dated May 16, 2024 (the "Delinquency Letter"), notifying the Company that it is not in compliance with the requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) because it did not timely file its annual report on Form 20-F for the year ended December 31, 2023 (the "2023 20-F"). In accordance with Nasdaq Listing Rules, the Company has 60 calendar days from the date of the Delinquency Letter to submit a plan to regain compliance with Nasdaq Listing Rules (the "

SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly app

Procaps Group (NASDAQ:PROC) ("Procaps"). Having completed the last ordinary meeting of 2023 on December 19th in which Ruben Minski acted as CEO of the Procaps Group for the last time, and taking into account that as of January 15th, 2024 he will take over as Executive Chairman of the Board, which resulted from a planned and communicated process to the market since February of this year, we would like to express our appreciation to Ruben for his inspiring and visionary leadership that has allowed Procaps to be a leading organization in the pharmaceutical sector in the Region today, recognized and valued in the market by the different stakeholders. Throughout his career in the Organization,

Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today a strategic leadership transition as Ruben Minski, founder and CEO of Procaps prepares to transition from the role of Chief Executive Officer to focus exclusively on his role as Executive Chairman of the Board, and the appointment of Jose Antonio Vieira as the new Chief Executive Officer of Procaps Group. The transition will be effective January 15, 2024. After over 45 years of visionary leadership and dedicated service, Ruben Minski has played a pivotal role in Procaps' growth and success, transforming it into a global leader in pharmaceutical innovation. Under

Experienced Pharma Professional Brings Wealth of International Industry and Governance Experience to Board Procaps Group (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced the appointment of one new member to its Board of Directors (the "Board"). On October 23, 2023, the Board appointed Sandra Sánchez y Oldenhage as a Director to fill the current vacancy on the Board, effective immediately and for a period ending at its annual general meeting of shareholders for the fiscal year ended December 31, 2023. Sandra Sánchez y Oldenhage has over 35 years' experience in steering mature, start-up, and turn-around/re

Pharmaceutical Industry and Investor Relations Veteran to Lead Capital Markets Communications Strategy Procaps Group (NASDAQ:PROC), a leading integrated international healthcare and pharmaceutical company, today announced the appointment of Melissa Angelini as Investor Relations Director, effective February 1, 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220128005310/en/Melissa Angelini, Procaps Group Investor Relations Director (Photo: Business Wire) Melissa Angelini is a seasoned executive with over 15 years of experience in capital markets and investor relations with healthcare and pharmaceutical companies. She has ex

Net Revenues Increased 5% in 9M23 Year-over-Year on a Constant Currency Basis, Driven by 13% RX Growth Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company, today announced its financial results for the three months ended September 30, 2023 ("3Q23") and the nine months ended September 30, 2023 ("9M23"). Financial Highlights 3Q23 & 9M23 Net revenues totaled $118 million for 3Q23, positively impacted by the performance of RX and OTC portfolios, offset by lower CDMO revenues. On a constant currency basis, net revenues increased by 2% in 3Q23. For 9M23, net revenues totaled $313 million, an incre

Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is postponing the previously-announced earnings conference call (currently scheduled for November 16, 2023) to a later date after Procaps publishes its results for the third quarter and nine months ended September 30, 2023 ("3Q23"). Procaps will host a conference call in conjunction with its release of the 3Q23 Results, and call/webcast details will be provided in advance of the call. About Procaps Group Procaps Group, S.A. ("Procaps") (NASDAQ:PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplie

Company to Host Conference Call on Thursday November 16, 2023 at 10:30 a.m. Eastern Time Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, announced it will report its results for the third quarter and nine months ended September 30, 2023, after market closes on Tuesday, November 14, 2023. The Company will host a conference call and webcast on Thursday, November 16, 2023, at 10:30 a.m. Eastern time, to discuss the third quarter and nine months 2023 results. To access the call, please use the following information: Date: Thursday, November 16, 2023 Time: 10:30 a.m. ET Webcast: Cli

Net Revenues Increased 7% in 1H23 Year-over-Year, on a Constant Currency Basis, Signaling Positive Performance of Rx Products Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company, today announced its financial results for the three months ended June 30, 2023 ("2Q23") and the six months ended June 30, 2023 ("1H23"). "Amidst a challenging 2Q23, we are accelerating our strategic plan, bolstered by operational agility. While short-term impacts were expected, we believe our proactive approach to cost-cutting positions us for a resilient 4Q23. We are addressing cash flow concerns, adapting pricing str

Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, announced that it will report its results for the second quarter and six months ended June 30, 2023, before market opens on Tuesday, September 5, 2023. The Company will host a conference call and webcast at 11:00 a.m. Eastern time, on the same day, to discuss the second quarter and first half 2023 results. To access the call, please use the following information: Date: Tuesday, September 5, 2023 Time: 11:00 a.m. ET Webcast: Click here to access Toll Free dial-in number: 1-844-204-8586 Toll/Internationa

Constant Currency Net Revenues Increased 7% Year-over-Year in 2022, With Strong Demand of RX and Softgel Portfolios, Offset by Clinical Specialty Covid Portfolio Preliminary Results for 1Q23 Show a Significant Rebound from 4Q22 Performance, Company Expects to Reach at Least High Single-Digit Growth in Adjusted EBITDA Management Reaffirms Preliminary FY2023 Net Revenue and Adjusted EBITDA Guidance Multiple Value-Creation Initiatives Implemented and On Track to Achieve Up to $15 million of Targeted Recurring Savings Company to Host Conference Call and Webcast Monday, May 15, 2023 at 10:00am Eastern Time Procaps Group S.A. (NASDAQ:PROC) ("Procaps"), a leading integrated international

MIAMI and BARRANQUILLA, Colombia, May 01, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today that it will file its Form 20-F and publish its Full Year 2022 Earnings Release before May 15th. The delay in filing the 2022 Form 20-F is because additional time is necessary to prepare and complete the internal review of the Company's financial statements for the year ended December 31, 2022. Procaps is making every effort to file its 2022 Form 20-F as soon as practicable. In conjunction with the 20-F filing, Procaps will publish its Full Year 2022 Earnings Release and ho

Reports Preliminary Financial Estimates for Net Revenue and Adjusted EBITDA for Full Year 2022 Realigns Board of Directors to Focus on Profitable Growth Announces $5M+ Share Repurchase Program Commences $15MM Cost Reduction Plan to Improve Margins and Financial Performance 20-F & Conference Call for Q4 and FY 2022 Financial Results Expected to Occur in March 2023 MIAMI and BARRANQUILLA, Colombia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today issued a letter to shareholders from Ruben Minski, Chairman of the Board and CEO of Procaps, including preliminary select f

MIAMI and BARRANQUILLA, Colombia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Procaps Group S.A. (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced its financial results for the three months ended September 30, 2022 ("3Q22") and the nine months ended September 30, 2022 ("9M22"). "Demand remains robust for RX and consumer health products as well as for all our CDMO products, and gross margin remained strong despite the challenging macro scenario we have been facing. We have continued to invest and prepare the company for the organic and inorganic growth that is about to come, and we expect to see continued revenue growth and improved ope

MIAMI and BARRANQUILLA, Colombia, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that it expects to report its results for the third quarter ended September 30, 2022, after the market closes on Monday, November 14, 2022. The Company expects to host a conference call and webcast at 04 p.m. Eastern time, on November 16, 2022.To access the call, please use the following information: Date:Wednesday, November 16, 2022Time:04 p.m. ETToll Free dial-in number:1-844-204-8586Toll/International dial-in number:1-412-317-6346Procaps HD Phone:https://bit.ly/PROCHDPHONEConference ID:Procaps Group